Total
0
Shares
Alzheimer’s treatment breakthrough sends Actinogen shares up 378 pc
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cann Global's (CGB) joint venture (JV) partner has been handed a key export permit, which will allow its cannabis hard pills to be shipped to Australia
  • Canntab Therapeutics has been given the green light by Health Canada, meaning Cann Global can begin importing the products
  • The patented pills from Canntab are unique as they allow for precise dosing
  • CGB plans to order six different products from the pill range
  • Among the pills Cann Global has ordered are two THC products, two CBD products and two THC/CBD blends
  • The products will begin arriving in Australia next month and will be available through the Special Access Scheme B and Authorised Prescriber schemes
  • Shares in Cann Global have opened Tuesday trading steady at 0.8 cents per share

Cann Global's (CGB) joint venture (JV) partner has been handed a key export permit, which will allow its cannabis hard pills to be shipped to Australia.

Canntab Therapeutics has been given the green light by Health Canada, while Cann Global has already secured the necessary import permits for the pills.

Following the export permit being issued, Cann advises that its order of the hard pill products will begin arriving in Australia next month.

Canntab's products are unique because of the patented hard pill form which they come in, which allows for more precise dosing.

CGB has ordered six different products from its JV partner, including two THC products, two CBD products and two THC/CBD blends.

The CBD and THC pills will be available in Australia through both the Special Access Scheme B and Authorised prescriber schemes.

Cann is also planning to make the pills available to the Cannabinoid Medicine Observational Study (CMOS) which is testing the efficacy of cannabis on neurological and mental health conditions.

Shares in Cann Global have opened Tuesday trading steady at 0.8 cents per share at 10:06 am AEDT.

CGB by the numbers
More From The Market Herald
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr. Christian Behrenbruch - The Market Herald

" TGA fast tracks evaluation of Telix Pharmaceuticals’ (ASX:TLX) cancer imaging product

The Theraputic Goods Administration (TGA) has commenced a priority evaluation process for Telix Pharmaceuticals’ (TLX) prostate cancer imaging product, Illuccix.
Pharmaxis (ASX:PXS) - CEO, Gary Phillips (left) - The Market Herald

" Pharmaxis (ASX:PXS) to raise $4.4M via placement

Pharmaxis (PXS) has received firm commitments to raise $4.4 million through a placement.
Universal Biosensors (ASX:UBI) - CEO, John Sharman - The Market Herald

" Universal Biosensors (ASX:UBI) toasts new distribution agreement for wine testing device

Universal Biosensors (UBI) has entered into a non-exclusive agreement with Singularity SpA to distribute its wine testing platform device in Chile.
Paradigm Biopharmaceuticals (ASX:PAR) - Chairman & CEO, Paul Rennie - The Market Herald

" Paradigm Biopharmaceuticals (ASX:PAR) enrols first participant in osteoarthritis trial

Paradigm Biopharmaceuticals (PAR) has enrolled its first patient in its knee osteoarthritis (OA) biomarker study in Box Hill, Victoria.